Market Research Logo

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Metastatic Adenocarcinoma of The Pancreas Overview
Therapeutics Development
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development
AbbVie Inc
Aduro BioTech, Inc.
Array BioPharma Inc.
Axcentua Pharmaceuticals AB
Berg LLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
CTI BioPharma Corp.
CytRx Corporation
Daiichi Sankyo Company, Limited
Eleison Pharmaceuticals LLC
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Incyte Corporation
MabVax Therapeutics Holdings, Inc.
Merrimack Pharmaceuticals, Inc.
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
Pfizer Inc.
Phoenix Biotechnology, Inc.
Targovax ASA
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXP-10711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-853520 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glufosfamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-5745 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2256098 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuMab-5B1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-52793 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MesoCART - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-05204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosedostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products
Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones
Featured News & Press Releases
Aug 04, 2016: Merrimack Provides Update on ONIVYDE
Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas
Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016
Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations
Jan 25, 2016: Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission
Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
    • The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
    • The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report

    ;